DONNA

TapImmune Announces Licensing Agreement with Mayo Clinic to Commercialize a Folate Receptor Alpha Vaccine for Multiple Cancer Indications

July 28th, 2015 | Posted In: Newsletter Articles, Research - Closer to the Finish

 Seattle WA, July 27, 2015 – TapImmune, Inc. (OTCQB: TPIV), a clinical stage cancer immunotherapy company is pleased to announce that the Company has exercised its option agreement with Mayo Clinic. TapImmune has signed a worldwide exclusive license agreement to commercialize a proprietary folate receptor alpha vaccine technology for all cancer indications. This technology, developed in the laboratory of Keith Knutson, Ph.D., at Mayo, has successfully completed Phase I clinical trials in ovarian and triple-negative breast cancer.

Read Complete Press Release (PDF)

Leave a Reply

Be the First to Comment!

Notify of
wpDiscuz

Stay Posted

Stay Posted

Locals Rule

Locals Rule

YesWay

YesWay

Team Donna

Team Donna

Donna partners

The Donna Foundation

The Donna Foundation

Jeff Galloway

Jeff Galloway

Mayo Clinic

Mayo Clinic

Learn More

First Coast News